Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00571506 · ClinicalTrials.gov registry record · Phase 4
Effect of Thiazolidinedione Treatment Vascular Risk Markers
A Phase 4 study of Diabetes Mellitus, Type 2 and Vascular Diseases, sponsored by University of Arkansas.
- Completed
- Registry status
- Phase 4
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT00571506: Completed Phase 4 study of Diabetes Mellitus, Type 2 and Vascular Diseases, sponsored by University of Arkansas.
NCT00571506 is a Phase 4 study of Diabetes Mellitus, Type 2 and Vascular Diseases that has completed, run by University of Arkansas. The registered enrollment target is 25 participants, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00571506, a Phase 4 study of Diabetes Mellitus, Type 2 and Vascular Diseases, has completed, sponsored by University of Arkansas.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to examine the effects of two diabetes medications, rosiglitazone and pioglitazone, on markers of vascular disease in subjects with type 2 diabetes.
Conditions Studied
Interventions
- DRUG Rosiglitazone
- DRUG Pioglitazone
Study Locations (1)
Arkansas
- University of Arkansas for Medical Sciences - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2004-05 |
| Est. Completion | 2007-08 |
| Phase | Phase 4 |
What the finished NCT00571506 record still lists
NCT00571506 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (99% lower).
The record links to 2 conditions, with Diabetes Mellitus, Type 2 appearing as the primary indexed condition, and to 2 interventions - of which Rosiglitazone is the first listed.
NCT00571506 reports a single indexed study location in Arkansas.
Frequently Asked Questions
What is clinical trial NCT00571506 about?
NCT00571506 is a clinical study titled "Effect of Thiazolidinedione Treatment Vascular Risk Markers". The purpose of this study is to examine the effects of two diabetes medications, rosiglitazone and pioglitazone, on markers of vascular disease in subjects with type 2 diabetes.
What is the current status of trial NCT00571506?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 25 participants. The study started on 2004-05. Estimated completion is 2007-08.
What conditions does trial NCT00571506 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Type 2, Vascular Diseases.
What interventions are being tested in trial NCT00571506?
The interventions under investigation include: Rosiglitazone (DRUG), Pioglitazone (DRUG).
Who is sponsoring clinical trial NCT00571506?
This trial is sponsored by University of Arkansas, which has 318 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00571506 being conducted?
This trial has 1 study location across Arkansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus, Type 2
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00571506's enrollment target sits among peer trials
25 308th of 348 higher than 39 of 348 other Diabetes Mellitus, Type 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetes Mellitus, Type 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Effects of Semaglutide on Intracranial Blood Flow and Brain-Barrier Permeability in Type-2 Diabetes
RECRUITING · Phase 4
-
Knee Osteoarthritis Treatment With Zilretta vs. Kenalog in the Context of Type II Diabetes
RECRUITING · Phase 4
-
Effect of Continuing Versus Holding Metformin During Hospitalizations.
RECRUITING · Phase 4
-
Surgical or Medical Treatment
ACTIVE NOT RECRUITING · Phase 4
-
Afrezza® Dosing Optimization Study
COMPLETED · Phase 4
-
Impact of Dietary Intervention on Weight Change in Subjects With Type 2 Diabetes
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia